Kane Biotech was preparing the annual financial statements and, as part of the year-end procedures, assessed the assets and prepared the following alphabetized schedule based on adjusted values at December 31, 2023: (Do not round intermediate calculations. Round final answers to nearest whole dollar.) Asset Equipment Furniture Land Date of Purchase May 1/18 Deprec. Method* Cost Units $ 59,000 Residual Value $ 5,240 Useful Life Jun. 28/18 DDB 26,000 Apr. 5/18 N/A 99,000 3,400 N/A 8,400 units 8 yrs Accum. Deprec. $ 34,560 Recoverable Amount $ 8,240 N/A 21,689 N/A office building Warehouse Apr. 5/18 SL 105,000 Apr. 5/18 SL 76,000 29, 600 24,000 15 yrs 35,600 4,850 115,800 66,500 20 yrs 26,938 59,100 *DDB = Double-declining-balance; SL = Straight-line; Units = Units-of-production; N/A = Not applicable Required: 1. Record any impairment losses at December 31, 2023. Assume Kane Biotech has recorded no impairment losses in previous years View transaction list View journal entry worksheet No Date General Journal 1 Dec 31, 2023 Impairment loss Equipment Office building Debit Credit 19,100 16,200 2,900 2. Record depreciation for each asset at December 31, 2024. Assume that there was no change in the residual values or useful lives regardless of any impairment losses that might have occurred. The equipment produced 2,500 units during 2024. View transaction list Journal entry worksheet < 1 2 3 4 Record the revised depreciation on equipment. Note: Enter debits before credits. Date December 31, 2024 General Journal Debit Credit View general journal Clear entry Record entry